You do not have inside information about what Merck is interested in—you cannot speak for any BP company. Like the rest of us, you only have access to publicly available information…
✅️ Merck’s pembrolizumab is being studied in combo with multiple DC platforms licensed to NWBO, and Dr. Kalinski recently cited MTA agreements with Merck.
Below is one very noteworthy example of DC vaccine in combo with TLR & PD1 blockade. We will see what comes next. There are multiple TLR agonist agents, multiple checkpoint inhibitors, and NWBO has in-licensed multiple dendritic cell platforms. Partnership(s) & collaborations announcements could include any of the companies that make TLR agonists or checkpoint inhibitors.
Market Data 
Markets 
